West outlines plans for Ireland insulin injector plant and future expanisons

By Agnes Shanley

- Last updated on GMT

Related tags Future

West outlines plans for Ireland insulin injector plant and future expanisons
West Pharmaceutical Services plans to expand its global manufacturing operations with a new site in Waterford, Ireland.

The plant will make packaging components for insulin injector cartridges, and is expected to bring another 150 new jobs to the area.  Construction of the 44-acre site at Knockhouse on Old Kilmeaden Road, is expected to start early next year. 

The facility is being designed to accommodate expansion for multiple product lines, and will be a center of excellence for West’s proprietary elastomeric sheeting, which is used to package insulin for use in pen injectors.  

”The seals are the critical functional part of the cartridge in the insulin pen system, and must meet the demands of preserving insulin efficacy and stability while being in direct contact with the drug material,”​ according to Don McMillan, Vice President of Operations for West P Pharmaceutical Packaging Systems.

Future plans include additional manufacturing space for West’s proprietary injectable component product lines, which are integral to many injectable and dosage forms, including Westar, a specialized sterilization process, McMillan says. With these expansions, the plant eventually could accommodate between 250 to 300 jobs and involve an investment in the range of €100m ($125m).

“Right now, our plans are focused primarily on manufacturing, although we will be performing process optimization and prices development work in Waterford,”​ said MacMillan.  “Most of our traditional R&D and design work happens at different offices, although the campus concept allows for us to consider performing this function on site in the future,”​ he adds.

“We will adjust our plans periodically,”​ he continued, adding that “depending on customer demand, it’s our intention to continue expansions into 2020.”

Business friendly

The company considered several locations before settling on Ireland. “In general, it’s a very business-friendly environment, and it’s now home to many healthcare companies, many of which are current customers,”​ said MacMillan. “So its burgeoning life-science footprint is also attractive to us.” 

West has had a presence in Ireland since 2005, with a manufacturing and development center in Dublin, which is the European headquarters for The Tech Group, a West subsidiary which specializes in providing device design, development and manufacturing services for pharmaceutical and med-tech customers.

West employs over 230 people at its Mulhuddart, Dublin facility, which is also being expanded to meet increased demand.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars